Instruction for use: Flunisolide (Flunisolidum)

Pharmacological group

Glucocorticosteroids

Nosological classification (ICD-10)

J30 Vasomotor and allergic rhinitis

Allergic rinopatiya, Allergic rhinosinusopathy, Allergic respiratory diseases, Allergic rhinitis, nasal allergy, Seasonal Allergic Rhinitis, Vasomotor rhinitis, Long-allergic rhinitis, Perennial allergic rhinitis, Perennial allergic rhinitis, Year-round or seasonal allergic rhinitis, Year-round allergic rhinitis nature, Rhinitis allergic vasomotor, Exacerbation of pollen allergy in the form of Syndrome rinokonyunktivalnogo, Acute allergic rhinitis, Edema of the nasal mucosa, Edema of the nasal mucosa, Swelling of the mucosa of the nasal cavity, Swelling of the nasal mucosa, Swelling of the nasal mucosa, pollen disease, Permanent allergic rhinitis, rhinoconjunctivitis, rhinosinusitis,rhinosinusopathy, Seasonal allergic rhinitis, Seasonal Allergic Rhinitis, Haymarket rhinitis, Chronic allergic rhinitis, Allergic respiratory diseases

J44 Other chronic obstructive pulmonary disease

Allergic bronchitis, Bronchitis asthma, Asthmatic bronchitis, wheeze bronchitis, Bronchitis is an obstructive, bronchi disease, Shortness of sputum in acute and chronic respiratory diseases, Cough in inflammatory diseases of the lung and bronchus, Reversible airflow obstruction, Reversible obstructive airway disease, Obstructive bronchitis disease, Obstructive lung disease, Obstructive bronchitis, Spastic bronchitis, Chronic lung disease, Chronic nonspecific lung diseases, Chronic obstructive pulmonary disease, Chronic obstructive bronchitis, Chronic obstructive airway disease, Chronic obstructive pulmonary disease, Restrictive lung pathology

J45 Asthma

Asthma physical effort, status asthmaticus, Bronchial asthma, Asthma lung flow, Bronchial asthma with obstruction of sputum discharge, Bronchial asthma heavy currents, Bronchial asthma physical effort, hypersecretory asthma, Hormone-dependent form of bronchial asthma, Relief of asthma attacks in bronchial asthma, Non-allergic asthma, nocturnal asthma, Exacerbation of asthma, Asthma attacks, Endogenous forms of asthma, Night asthma, Cough with bronchial asthma

Code CAS3385-03-3

Pharmacology

Pharmacological action - anti-inflammatory.

It breaks the metabolism of arachidonic acid and the synthesis of leukotrienes and PG (prostaglandins). After inhalation, 1 mg bioavailability is about 40%; Is rapidly converted into pulmonary pathways with the formation of sigma-beta-hydroxy metabolites and the metabolism of the "first passage" through the liver. Because of high presystemic metabolism when administered, bioavailability is even lower. Do not accumulate in the body, even when taking maximum doses. T1 / 2 - 1.8 h. It reduces the permeability of microvessels, inhibits the production and secretion of cytokines, prevents the direct migration and activation of inflammatory cells, increases the sensitivity of beta receptors of smooth muscles of the bronchi to beta-adrenomimetics.

Application of Flunisolide

Bronchial asthma, chronic obstructive bronchitis, allergic rhinitis.

Contraindications

Hypersensitivity, viral, bacterial and fungal infections of the oral cavity and bronchi, active tuberculosis, pregnancy (I trimester), children's age (up to 5 years).

Restrictions for use

Presence of ulcers of the nasal septum, recurrent nasal bleeding, with operations or injuries to the nose.

pregnancy and lactation

Action category for fetus by FDA - C.

Side effects

Oropharyngeal candidiasis, dysphonia, cough.

Routes of administration

Inhalation.